23 Feb 2010 07:00
23 February 2010
Toumaz Holdings Limited
Update on primary stages of clinical trials for Sensium digital plaster
Toumaz Holdings Limited (AIM:TMZ, 'Toumaz' or 'the Group'), a pioneer in low cost, ultra-low power wireless communications technology, has completed on schedule the primary two stages of its clinical trial of the Sensium "digital plaster" wireless body monitoring system. The trial was carried out at St Mary's Hospital, London.
This trial is a comparative study between the plaster and current state-of-the-art wired monitoring technology to assess the ability of the plaster to monitor vital signs ranging from normal conditions to elevated conditions. The data is now being analysed to optimise the device for future applications. The final stage of this trial will supplement the data collected in the primary two stages by evaluating the device's performance in a wider range of clinical conditions.
Further trials which will assess the whole system in a hospital ward environment are expected to start in H2 2010.
Professor Chris Toumazou, Chief Executive of Toumaz commented,
"We expect our ultra low power wireless technology to have real benefits in the medical sector and this first milestone is very encouraging in demonstrating the technology's viability in the healthcare arena."
Enquiries:
| Toumaz Holdings Limited | 020 7355 0036 |
| Chris Toumazou, Chief Executive Officer |
|
| Patrick Stephansen, Chief Financial Officer |
|
|
|
|
| FinnCap | 020 7600 1658 |
| Matthew Robinson/Henrik Persson |
|
|
|
|
| College Hill | 020 7457 2020 |
| Adrian Duffield/Rozi Morris |
|
Notes to editors:
About Toumaz Holdings Limited
Toumaz Holdings Limited is pioneering low cost, ultra-low power wireless infrastructure for sensory applications in a wide range of markets including medical monitoring.
Toumaz's smart sensor interface and transceiver platform - Sensium™ - enables non-intrusive, real-time wireless monitoring of multiple vital signs for a wide range of healthcare and lifestyle management applications. Based on Toumaz's patented ultra-low power Advanced Mixed Signal (AMx)™ technology, the Sensium provides the enabling technology to connect the mobile individual to healthcare providers - simply, affordably and unobtrusively.
For healthcare professionals, this transforms the possibilities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible, personalised healthcare, as well as better therapeutic outcomes.
Toumaz's patented wireless infrastructure technologies are also applicable to numerous other markets including consumer devices such as internet-connected radios and home and environmental monitoring, based on their compelling combination of high performance, low power and low cost.
About Sensium
The Sensium digital plaster is based on new generation Sensium™ wireless technology, designed and developed by Toumaz. It provides a complete infrastructure to allow healthcare providers to non-intrusively monitor the human body continuously, wirelessly and intelligently and at low-cost.
FST.L (FST)